Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 30 September 1988:
Vol. 241. no. 4874, pp. 1820 - 1823
DOI: 10.1126/science.3051378
Prev | Table of Contents | Next

Articles

Science, Vol 241, Issue 4874, 1820-1823
Copyright © 1988 by American Association for the Advancement of Science

articles

Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates

RE Donahue, J Seehra, M Metzger, D Lefebvre, B Rock, S Carbone, DG Nathan, M Garnick, PK Sehgal, D Laston, and al. et

Genetics Institute, Cambridge, MA 02140.

Interleukin-3 (IL-3) is a member of a family of growth factors, each of which supports the proliferation and development of hematopoietic precursors in culture. Although the biologic effects of the different hematopoietic growth factors have been well documented in different culture systems, it has only recently become possible to study the activities of these molecules in vivo. In comparison with the later acting hematopoietic growth factors granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor, IL-3 elicited a delayed and relatively modest leukocytosis when continuously infused intravenously in primates. The IL-3 infusion, however, greatly potentiated the responsiveness of the animal to subsequent administration of a low dose of GM-CSF. These results suggest that IL-3 expands an early cell population in vivo that subsequently requires the action of a later acting factor such as GM-CSF to complete its development. Optimal stimulation of hematopoiesis may be achieved with combinations of hematopoietic growth factors.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation.
Y. Wang, D. Cai, C. Brendel, C. Barett, P. Erben, P. W. Manley, A. Hochhaus, A. Neubauer, and A. Burchert (2007)
Blood 109, 2147-2155
   Abstract »    Full Text »    PDF »
Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide.
P. Papaldo, M. Lopez, P. Marolla, E. Cortesi, M. Antimi, E. Terzoli, P. Vici, C. Barone, G. Ferretti, S. Di Cosimo, et al. (2005)
J. Clin. Oncol. 23, 6908-6918
   Abstract »    Full Text »    PDF »
Thrombopoietic Factors in Chronic Bone Marrow Failure States: The Platelet Problem Revisited.
R. Kurzrock (2005)
Clin. Cancer Res. 11, 1361-1367
   Abstract »    Full Text »    PDF »
Leridistim, a Chimeric Dual G-CSF and IL-3 Receptor Agonist, Enhances Multilineage Hematopoietic Recovery in a Nonhuman Primate Model of Radiation-Induced Myelosuppression: Effect of Schedule, Dose, and Route of Administration.
A. M. Farese, D. B. Casey, W. G. Smith, R. M. Vigneulle, J. P. McKearn, and T. J. MacVittie (2001)
Stem Cells 19, 522-533
   Abstract »    Full Text »
Mobilization of Peripheral-Blood Stem Cells by Concurrent Administration of Daniplestim and Granulocyte Colony-Stimulating Factor in Patients With Breast Cancer or Lymphoma.
J. F. DiPersio, M. W. Schuster, C. N. Abboud, J. N. Winter, V. R. Santos, D. M. Collins, J. W. Sherman, and C. M. Baum (2000)
J. Clin. Oncol. 18, 2762-2771
   Abstract »    Full Text »    PDF »
Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression.
T. J. MacVittie, A. M. Farese, W. G. Smith, C. M. Baum, E. Burton, and J. P. McKearn (2000)
Blood 95, 837-845
   Abstract »    Full Text »    PDF »
Correlation Between IL-3 Receptor Expression and Growth Potential of Human CD34+ Hematopoietic Cells from Different Tissues.
S. Huang, Z. Chen, J. F. Yu, D. Young, A. Bashey, A. D. Ho, and P. Law (1999)
Stem Cells 17, 265-272
   Abstract »    Full Text »
The Common Marmoset as a Target Preclinical Primate Model for Cytokine and Gene Therapy Studies.
H. Hibino, K. Tani, K. Ikebuchi, M.-S. Wu, H. Sugiyama, Y. Nakazaki, T. Tanabe, S. Takahashi, A. Tojo, S. Suzuki, et al. (1999)
Blood 93, 2839-2848
   Abstract »    Full Text »    PDF »
Comparative Effects of Three Cytokine Regimens After High-Dose Cyclophosphamide: Granulocyte Colony-Stimulating Factor, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), and Sequential Interleukin-3 and GM-CSF.
A. Ballestrero, F. Ferrando, A. Garuti, P. Basta, R. Gonella, P. Stura, G. S. Mela, M. Sessarego, M. Gobbi, and F. Patrone (1999)
J. Clin. Oncol. 17, 1296
   Abstract »    Full Text »    PDF »
Involvement of Interleukin-3 in Delayed-Type Hypersensitivity.
N. Mach, C. S. Lantz, S. J. Galli, G. Reznikoff, M. Mihm, C. Small, R. Granstein, S. Beissert, M. Sadelain, R. C. Mulligan, et al. (1998)
Blood 91, 778-783
   Abstract »    Full Text »    PDF »
IL-3 in the Clinic.
M. Eder, G. Geissler, and A. Ganser (1997)
Stem Cells 15, 327-333
   Abstract »    Full Text »
PIXY 321 (GM-CSF/IL-3 Fusion Protein).
R. Secola (1993)
Journal of Pediatric Oncology Nursing 10, 117-118
   PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)